Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas - Wikidata - awgldk - TriplyDB

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

http://www.wikidata.org/entity/Q33900906

about

Comprehensive pharmacological profiling of neurofibromatosis cell lines.Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.An update on genomic-guided therapies for pediatric solid tumors.Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.RAS Proteins and Their Regulators in Human Disease.Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem.SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.BCRP expression in schwannoma, plexiform neurofibroma and MPNST.Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children's Oncology Group report.Pediatric Low-Grade Gliomas: Next Biologically Driven Steps.The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation.Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer.Optic Pathway Gliomas in Neurofibromatosis Type 1.Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights.New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs.MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?Spinal and Paraspinal Plexiform Neurofibromas in Patients with Neurofibromatosis Type 1: A Novel Scoring System for Radiological-Clinical Correlation.Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study.Recent Advances in Intradural Spinal Tumors.Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.Restoring functional neurofibromin by protein transduction.Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis.Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.Comprehensive genomic profiling of malignant phyllodes tumors of the breast.The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.Targeted therapies: Selumetinib MEKing differences in NF1.Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors.Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas

P2860

Q33622690-EABDF353-44E0-4839-BF28-FFC564BA01DE Q36389964-C2686E88-835D-4494-AC2E-402143AE368B Q37640687-F3C388F5-BDD1-4BCE-A460-483D90300285 Q38673827-C7AE1219-8433-43B9-AB83-CBA7904F11E0 Q38738733-2F16D635-2CF8-4211-93FE-228E2CBC509C Q39407402-25E602E1-AC63-40D1-B625-6D023C25D219 Q41582116-92A2BA27-DC59-404C-B363-04ED49B605D2 Q41600985-F0016227-E556-439E-928F-BCB6BA81BFCA Q42275107-6CB06484-3FBA-492F-A45E-5E64666B04F7 Q45955739-BDDBE21E-7528-4DF4-AD7E-9095589E44BE Q46067854-8D52AA81-9514-49DD-99FA-8413E5A443F4 Q46624842-D4736E13-A6BE-4CF5-983C-4371E96A735C Q46667195-4CBCFD7C-24E7-4C4F-8073-8EE0F3FC3B82 Q47123485-1D19219E-3669-439D-B750-EE54199D58DB Q47227758-EDEBE813-1B1E-41FB-AE9E-A7868CDB2817 Q47432675-076F3DAA-E018-4E07-85D3-7EF480435B4D Q47712403-7EFD2741-B83D-45A2-962A-D5302CFC0263 Q47779215-85C8560A-EF91-49DE-AACD-EDEB36618C78 Q47793357-4483E5D5-3E56-4870-966D-3A7891AB8276 Q47887929-7166386E-1383-4318-833A-F65408C99343 Q47934716-3C98BD48-618F-46ED-9E22-E5A59E177910 Q48141393-B9143E93-B13F-498C-9534-98483638303F Q48229235-D09A75F8-9BE7-4352-92C8-51B7E3167C92 Q48256644-32E85637-328F-43F8-A72E-4C24373247F0 Q49549866-36859AE6-F535-48BF-B0EF-61EC039EFB3C Q50027408-A40E3C9B-0F5C-40A3-8E2A-8794A8EE6AC9 Q50089792-BD0C7E21-17F6-4341-B2BD-83E1A9D58E7B Q52579455-E3A0F302-8719-429C-BC71-7C919D3F9B44 Q52607333-A2B4275B-D19D-4DAC-BEE2-ACDBCE87689D Q52622505-1A110614-0DC6-4C90-A16D-C95F29E5EA4C Q52673571-05CE51F1-8779-4E30-AF0D-9F9B51E26E17 Q52905583-E5571ECB-284E-4D1D-807C-062ABC43C58D Q53338183-98F301E8-643E-4559-BC72-9A679B4C7685 Q54154074-CCD68043-92BC-4AC3-A1E2-936676925F09 Q55282871-D2006D95-39AD-4D7F-82E6-480928FAB9B9 Q58699185-59C1226D-1994-4B6C-B4C4-6170327BC01C

P2860

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

http://www.wikidata.org/entity/Q33900906

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

@ast

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

@en

type

label

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

@ast

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

@en

prefLabel

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

@ast

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

@en

P1433

Q33900906-AC4C0EF1-489C-4414-8255-A5A89ADA1BDD

P1476

Q33900906-1DD88E88-F0B0-4D1C-B205-BA17E2E699D9

P2093

Q33900906-09E74DE5-B245-4EAF-859E-2309BDE5B63C

Q33900906-1F34B4B8-F114-4995-9AC6-0C6E3645C4D5

Q33900906-42ACC6BE-AB31-4E84-B4E7-FD30B4BD251A

Q33900906-4BEEE6CC-E604-4ACA-B0CC-5D4CF1539FB3

Q33900906-524B05A7-869D-477A-A96C-E6FC485E28A1

Q33900906-54F4A72F-94E7-4BDA-898A-5EB2ECC90C9B

Q33900906-5E2F3757-4743-4CEE-BE13-9919D1A597CD

Q33900906-63329651-FC2A-4107-98C5-A96E8A430C45

Q33900906-634DCD34-D0CF-4D08-8FD1-F8907380AE08

Q33900906-6A0FB958-02A2-4044-B722-D9901E67655B

P2860

Q33900906-0AB1783F-F692-4AF1-9D2B-3C341815F646

Q33900906-16796698-C7E9-4772-BEE6-F6D6AF369A1B

Q33900906-19C6C6C9-72F4-4E3C-850E-021DB7BE31AD

Q33900906-1E09508C-FE64-4FD4-8148-C9948F7E250C

Q33900906-28564CDD-5F1F-44B9-B378-913A468B9212

Q33900906-356A9F69-C097-4A30-AE2E-B77FF79475C9

Q33900906-3F54AB77-FE4B-4205-AB93-48EA5674906E

Q33900906-45EC1175-13D7-45D5-9D09-49BE8FA23667

Q33900906-4B770822-A397-45CE-A4FD-0C603931B371

Q33900906-4B7FEB55-617F-4AF6-8E3A-7DFB511C0389

P304

Q33900906-547CBC0A-7622-442A-A629-2D941B512ED4

P31

Q33900906-BE6DA8BA-8D10-4E32-AFEB-8A432707FF0F

P356

Q33900906-E86E2FF7-B443-4DFA-B39D-351E19841FFB

P407

Q33900906-DA90E5AD-F177-4BF1-B299-AA950907A113

P433

Q33900906-E78DA10D-2DDE-465B-AF66-31C10168A68D

P478

Q33900906-E8CE652A-9ED5-4112-9080-F05F1790E926

P577

Q33900906-7E56A0F1-515C-4137-97D4-BF1FFA42FB10

P698

Q33900906-07933B18-1565-4583-BA24-FBF8DA54673C

P932

Q33900906-A3317821-A080-450E-ACD6-6B3A21F2EC27

P356

P1433

The New England Journal of Medicine

P1476

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

@en

P2093

AeRang Kim

http://www.w3.org/2001/XMLSchema#string

Alessandra Brofferio

http://www.w3.org/2001/XMLSchema#string

Amy J Starosta

http://www.w3.org/2001/XMLSchema#string

Andrea Baldwin

http://www.w3.org/2001/XMLSchema#string

Andrea Gillespie

http://www.w3.org/2001/XMLSchema#string

Austin L Doyle

http://www.w3.org/2001/XMLSchema#string

Brian Weiss

http://www.w3.org/2001/XMLSchema#string

Brigitte C Widemann

http://www.w3.org/2001/XMLSchema#string

Elizabeth Schorry

http://www.w3.org/2001/XMLSchema#string

Eva Dombi

http://www.w3.org/2001/XMLSchema#string

P2860

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Plexiform neurofibromas in NF1: toward biologic-based therapy

NF1 tumor suppressor gene function: narrowing the GAP

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

P304

2550-2560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1605943

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28029918

http://www.w3.org/2001/XMLSchema#string

P932

5508592

http://www.w3.org/2001/XMLSchema#string